Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13426 - 13450 of 14784 in total
Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)).
Investigational
Matched Description: … of Postoperative Crohn's Disease (CD)). ... Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence …
Experimental
Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit
Matched Description: … Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America ... Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl …
TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT).
Investigational
Matched Description: … TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase …
rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
Investigational
LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.
Investigational
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Investigational
Matched Description: … MDX-1379 vaccine consists of two gp100 melanoma peptides. …
Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.
Investigational
Matched Description: … It is developed by MedImmune for the treatment of Allergic Rhinitis. ... Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic …
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of ... Trials of this drug have most likely been discontinued by the manufacturer. …
Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. It provides patients with long term therapeutic benefit from a single administration rather than multiple injections.
Investigational
IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III clinical trials.
Investigational
Matched Description: … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. …
According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)." It has been investigated as a lung cancer vaccine.
Investigational
Matched Description: … preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and
IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Investigational
Matched Description: … IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs). …
Displaying drugs 13426 - 13450 of 14784 in total